Literature DB >> 1613753

Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.

M Cushman1, D Nagarathnam, D Gopal, H M He, C M Lin, E Hamel.   

Abstract

A series of stilbenes has been prepared and tested for cytotoxicity in the five human cancer cell lines A-549 non-small cell lung, MCF-7 breast, HT-29 colon, SKMEL-5 melanoma, and MLM melanoma. The cis stilbenes 6a-f proved to be cytotoxic in all five cell lines, with potencies comparable to that of combretastatin A-4. These cytotoxic compounds were all potent inhibitors of tubulin polymerization. The corresponding trans stilbenes 7b-f were inactive as tubulin polymerization inhibitors and were significantly less cytotoxic in the five cancer cell lines. In the dihydro series, 8b, 8c, and 8f were inactive as tubulin polymerization inhibitors, while 8a, 8d, and 8e were less active than the corresponding cis compounds 6a, 6d, and 6e. The lack of tubulin polymerization inhibitory activity and cytotoxicity displayed by the phenanthrene 23b, which was synthesized as a conformationally rigid analogue of the lead compound 1, indicates that the activity of the stilbenes is not due to a totally planar conformation. Similarly, inactivity of the conformationally restricted analogue 26 suggests that the biologically active conformation of 1a resembles that of the cis alkene 1. Additional inactive compounds prepared include the benzylisoquinoline series 28-32 as well as the protoberberines 38 and 39. Shortening the two-carbon bridge of 1a to a one-carbon bridge in the diphenylmethane 20 resulted in a decrease in cytotoxicity and tubulin polymerization inhibitory activity. Although the corresponding benzophenone 18 was as active as 1a as a tubulin polymerization inhibitor, it was less cytotoxic than 1a, and the benzhydrol 19 was essentially inactive. With the exception of the amide 15c, which displayed low antitubulin activity, all of the phenylcinnamic acid derivatives 14a-c and 15a-f were inactive in the tubulin polymerization inhibition assay. The acid 14b and the ester 15a were cytotoxic in several of the cancer cell cultures in spite of their inactivity as tubulin polymerization inhibitors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613753     DOI: 10.1021/jm00090a021

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

1.  Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Delia Preti; Mojgan Aghazadeh Tabrizi; Andrea Brancale; Xian-Hua Fu; Jun Li; Su-Zhan Zhang; Ernest Hamel; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2011-12-21       Impact factor: 7.446

2.  Anti-tumor properties of cis-resveratrol methylated analogs in metastatic mouse melanoma cells.

Authors:  Valery L Morris; Tayyaba Toseef; Fathima B Nazumudeen; Christian Rivoira; Carmela Spatafora; Corrado Tringali; Susan A Rotenberg
Journal:  Mol Cell Biochem       Date:  2015-01-08       Impact factor: 3.396

3.  Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Filippo Prencipe; Valerio Bertolasi; Michela Cancellieri; Andrea Brancale; Ernest Hamel; Ignazio Castagliuolo; Francesca Consolaro; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2014-07-28       Impact factor: 7.446

4.  Highly potent triazole-based tubulin polymerization inhibitors.

Authors:  Qiang Zhang; Youyi Peng; Xin I Wang; Susan M Keenan; Sonia Arora; William J Welsh
Journal:  J Med Chem       Date:  2007-01-24       Impact factor: 7.446

5.  Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.

Authors:  Narsimha Reddy Penthala; Hongliang Zong; Amit Ketkar; Nikhil Reddy Madadi; Venumadav Janganati; Robert L Eoff; Monica L Guzman; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2014-12-29       Impact factor: 6.514

6.  Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Olga Cruz-Lopez; Manlio Tolomeo; Antonietta Di Cristina; Rosaria Maria Pipitone; Stefania Grimaudo; Jan Balzarini; Andrea Brancale; Ernest Hamel
Journal:  Bioorg Med Chem Lett       Date:  2010-11-21       Impact factor: 2.823

7.  Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Authors:  Patrick M Kelly; Niall O Keely; Sandra A Bright; Bassem Yassin; Gloria Ana; Darren Fayne; Daniela M Zisterer; Mary J Meegan
Journal:  Molecules       Date:  2017-08-31       Impact factor: 4.411

8.  Bacterial Catabolism of β-Hydroxypropiovanillone and β-Hydroxypropiosyringone Produced in the Reductive Cleavage of Arylglycerol-β-Aryl Ether in Lignin.

Authors:  Yudai Higuchi; Shogo Aoki; Hiroki Takenami; Naofumi Kamimura; Kenji Takahashi; Shojiro Hishiyama; Christopher S Lancefield; O Stephen Ojo; Yoshihiro Katayama; Nicholas J Westwood; Eiji Masai
Journal:  Appl Environ Microbiol       Date:  2018-03-19       Impact factor: 4.792

9.  A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.

Authors:  Euzébio G Barbosa; Luis A S Bega; Adilson Beatriz; Taradas Sarkar; Ernest Hamel; Marcos S do Amaral; Dênis Pires de Lima
Journal:  Eur J Med Chem       Date:  2008-12-25       Impact factor: 6.514

10.  SYNTHESIS AND BIOLOGICAL ACTIVITY OF SULFUR COMPOUNDS SHOWING STRUCTURAL ANALOGY WITH COMBRETASTATIN A-4.

Authors:  Edson Dos A Dos Santos; Paulo C Prado; Wanderley R de Carvalho; Ricardo V de Lima; Adilson Beatriz E; Dênis P de Lima; Ernest Hamel; Marzena A Dyba; Sergio Albuquerque
Journal:  Quim Nova       Date:  2013-02-01       Impact factor: 0.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.